These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 9915658)

  • 1. Effect of niacin on atherosclerotic cardiovascular disease.
    Guyton JR
    Am J Cardiol; 1998 Dec; 82(12A):18U-23U; discussion 39U-41U. PubMed ID: 9915658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease.
    Duggal JK; Singh M; Attri N; Singh PP; Ahmed N; Pahwa S; Molnar J; Singh S; Khosla S; Arora R
    J Cardiovasc Pharmacol Ther; 2010 Jun; 15(2):158-66. PubMed ID: 20208032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid-lowering drug use and cardiovascular events after myocardial infarction.
    Klungel OH; Heckbert SR; de Boer A; Leufkens HG; Sullivan SD; Fishman PA; Veenstra DL; Psaty BM
    Ann Pharmacother; 2002 May; 36(5):751-7. PubMed ID: 11978147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Niacin in Current Clinical Practice: A Systematic Review.
    Garg A; Sharma A; Krishnamoorthy P; Garg J; Virmani D; Sharma T; Stefanini G; Kostis JB; Mukherjee D; Sikorskaya E
    Am J Med; 2017 Feb; 130(2):173-187. PubMed ID: 27793642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Raising high-density lipoprotein cholesterol with niacin and fibrates: a comparative review.
    Sprecher DL
    Am J Cardiol; 2000 Dec; 86(12A):46L-50L. PubMed ID: 11374856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progression of coronary artery disease predicts clinical coronary events. Long-term follow-up from the Cholesterol Lowering Atherosclerosis Study.
    Azen SP; Mack WJ; Cashin-Hemphill L; LaBree L; Shircore AM; Selzer RH; Blankenhorn DH; Hodis HN
    Circulation; 1996 Jan; 93(1):34-41. PubMed ID: 8616937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trial clouds use of niacin with a statin.
    Harv Heart Lett; 2011 Aug; 21(12):2. PubMed ID: 21991606
    [No Abstract]   [Full Text] [Related]  

  • 8. Niacin: a powerful adjunct to other lipid-lowering drugs in reducing plaque progression and acute coronary events.
    Davidson MH
    Curr Atheroscler Rep; 2003 Sep; 5(5):418-22. PubMed ID: 12911853
    [No Abstract]   [Full Text] [Related]  

  • 9. Dramatic lowering of very high Lp(a) in response to niacin.
    Li M; Saeedi R; Rabkin SW; Frohlich J
    J Clin Lipidol; 2014; 8(4):448-50. PubMed ID: 25110227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ARBITER-2 : evidence that targeting HDL cholesterol slows atherosclerosis.
    Cardiovasc J S Afr; 2005; 16(1):61. PubMed ID: 15778778
    [No Abstract]   [Full Text] [Related]  

  • 11. Serial quantitative coronary angiography and coronary events.
    Mack WJ; Xiang M; Selzer RH; Hodis HN
    Am Heart J; 2000 Jun; 139(6):993-9. PubMed ID: 10827379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is HPS2-THRIVE the death knell for niacin?
    Toth PP; Murthy AM; Sidhu MS; Boden WE
    J Clin Lipidol; 2015; 9(3):343-50. PubMed ID: 26073392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapy and clinical trials.
    Elmallah W; Krasuski RA
    Curr Opin Lipidol; 2011 Dec; 22(6):512-3. PubMed ID: 22101564
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of niacin on the incidence of new onset diabetes and cardiovascular events in patients with normoglycaemia and impaired fasting glucose.
    Sazonov V; Maccubbin D; Sisk CM; Canner PL
    Int J Clin Pract; 2013 Apr; 67(4):297-302. PubMed ID: 23521322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of HDL-modifiers on cardiovascular outcomes: a meta-analysis of randomized trials.
    Verdoia M; Schaffer A; Suryapranata H; De Luca G
    Nutr Metab Cardiovasc Dis; 2015 Jan; 25(1):9-23. PubMed ID: 25439661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The therapeutic role of niacin in dyslipidemia management.
    Boden WE; Sidhu MS; Toth PP
    J Cardiovasc Pharmacol Ther; 2014 Mar; 19(2):141-58. PubMed ID: 24363242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical trial endpoints: angiograms, events, and plaque instability.
    Ballantyne CM
    Am J Cardiol; 1998 Sep; 82(6A):5M-11M. PubMed ID: 9766342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of intensive lipid lowering on coronary atheroma and clinical outcome.
    Houslay ES; Sarma J; Uren NG
    Heart; 2007 Feb; 93(2):149-51. PubMed ID: 17035507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of niacin in current clinical practice.
    Sharma A; Madan N
    Minerva Med; 2019 Feb; 110(1):79-83. PubMed ID: 30334440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project).
    Canner PL; Furberg CD; McGovern ME
    Am J Cardiol; 2006 Feb; 97(4):477-9. PubMed ID: 16461040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.